Xeris Biopharma officer sells 90,000 shares

Xeris Biopharma Holdings officer Kevin McCulloch reported an open-market sale of 90,000 shares of common stock at a weighted average price of $8.0279 per share on July 1, 2026.

Rhea-AI Filing Summary

Xeris Biopharma Holdings officer Kevin McCulloch reported an open-market sale of 90,000 shares of common stock at a weighted average price of $8.0279 per share on July 1, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.

After the transaction, McCulloch directly owns 1,691,126 shares of Xeris Biopharma common stock. An additional 25,000 shares are held indirectly by his spouse, including 3,401 shares acquired on June 30, 2026 under the company’s 2018 Employee Stock Purchase Plan, with beneficial ownership of those indirect shares disclaimed except for any pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 90,000 shares

Net Sell 2 txns

Insider McCulloch Kevin

Role See Remarks

Sold 90,000 shs ($723K)

Type	Security	Shares	Price	Value
Sale	Common Stock	90,000	$8.0279	$723K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,691,126 shares (Direct); Common Stock — 25,000 shares (Indirect, By Spouse)

Footnotes (4)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person as of September 4, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. Includes 3,401 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.
4. F4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares sold: 90,000 shares Weighted average sale price: $8.0279 per share Direct holdings after sale: 1,691,126 shares +2 more

5 metrics

Shares sold 90,000 shares Open-market sale on July 1, 2026

Weighted average sale price $8.0279 per share Common stock sale on July 1, 2026

Direct holdings after sale 1,691,126 shares Common stock owned directly after transactions

Indirect spouse holdings 25,000 shares Common stock held by spouse, indirect ownership

ESPP shares acquired 3,401 shares Acquired June 30, 2026 under 2018 Employee Stock Purchase Plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, 2018 Employee Stock Purchase Plan, beneficial ownership, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person as of September 4, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.10, inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

2018 Employee Stock Purchase Plan financial

"Includes 3,401 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended."

beneficial ownership regulatory

"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16 regulatory

"shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xeris Biopharma (XERS) report for Kevin McCulloch?

Xeris Biopharma reported that officer Kevin McCulloch sold 90,000 shares of common stock. The sale occurred on July 1, 2026 at a weighted average price of $8.0279 per share through multiple transactions within a disclosed price range.

At what price did Kevin McCulloch sell Xeris Biopharma (XERS) shares?

Kevin McCulloch’s 90,000 Xeris Biopharma shares were sold at a weighted average price of $8.0279. The filing notes the shares were sold in multiple trades at prices ranging from $8.00 to $8.10 per share, inclusive, on July 1, 2026.

How many Xeris Biopharma (XERS) shares does Kevin McCulloch own after the reported sale?

Following the reported sale, Kevin McCulloch directly owns 1,691,126 Xeris Biopharma common shares. The filing also shows 25,000 additional shares held indirectly by his spouse, with beneficial ownership of those indirect holdings disclaimed except for any pecuniary interest.

Was Kevin McCulloch’s Xeris Biopharma (XERS) share sale pre-planned?

Yes. The sale was effected under a Rule 10b5-1 trading plan adopted by Kevin McCulloch on September 4, 2025. Such plans allow insiders to schedule trades in advance, providing a structured framework separate from day-to-day discretionary trading decisions.

What does the Form 4 say about Xeris Biopharma (XERS) shares held by Kevin McCulloch’s spouse?

The Form 4 shows 25,000 Xeris Biopharma shares held indirectly by Kevin McCulloch’s spouse, including 3,401 acquired on June 30, 2026 under the 2018 Employee Stock Purchase Plan. McCulloch disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:40 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		90,000	D	$8.0279(2)	1,691,126(3)	D
Common Stock								25,000(4)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person as of September 4, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 3,401 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.

4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)